This site is intended for health professionals only

Published on 26 October 2009

Share this story:

Merck KGaA revenues increase by 2.7% to €1.9 billion


Rebif sales rise 13% to €381 million; Erbitux sales up 33% to ‚€177million. Liquid Crystals climbing, revenues at‚ €211 million. R&D expenses up 17% to‚ €333 million. Group guidance for 2009 confirmed and refined.

Merck KGaA announced today that Group total revenues rose 2.7% in the third quarter to €1,944 million from €1,893
million in the year-ago quarter as the Pharmaceuticals divisions continued to grow and the Chemicals divisions continued to recover from the economic crisis.

Royalty income declined 9.7% to €82 million.

Mainly due to inventory adjustments and under utilisation of capacities, the gross margin was little changed compared to the year-ago quarter at €1,422 million.

For more information, please click the link below.

Merck KGaA

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: